Search results for "Rating"

showing 10 items of 2021 documents

Fear of cancer progression in patients with stage IA malignant melanoma.

2018

We aimed to determine the prevalence and importance of fear of cancer progression (FoP) in melanoma patients with stage IA tumours to assess psychosocial and demographic factors associated with severity of FoP and to determine the relationship of FoP and quality of life (QoL). One hundred and thirty-six patients with stage IA melanoma completed the short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS) and the EORTC-QLQ-C30. We found a mean FoP-Q-SF sum score of 30.2 points (±8.4 points SD). In this study, 33% of patients reported high FoP at or above the cutoff-value of 34 points. Higher FoP was found in women (p < 0.01), young (…

OncologyAdultMalemedicine.medical_specialtyMedizinAnxietyHospital Anxiety and Depression Scale03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicinemedicinePrevalenceHumans030212 general & internal medicineStage (cooking)MelanomaDepression (differential diagnoses)AgedAged 80 and overPsychiatric Status Rating Scalesbusiness.industryCancerFearMiddle Agedmedicine.diseasehumanitiesLogistic ModelsOncologyPhobic Disorders030220 oncology & carcinogenesisDisease ProgressionQuality of LifeAnxietyFemaleSkin cancermedicine.symptombusinessPsychosocialEuropean journal of cancer care
researchProduct

A monoamine oxidase B gene variant and short-term antidepressant treatment response.

2007

Genetic differences among patients suffering from Major Depression are likely to contribute to interindividual differences in medication treatment response. Thus, the identification of gene variants affecting drug response is needed in order to be able to predict response to psychopharmacological drugs. This study analyzed a possible association of the common A644G single nucleotide polymorphism (SNP) within intron 13 of the monoamine oxidase B (MAOB) gene with antidepressant treatment response. The study population consisted of n = 102 patients with major depression (criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV) participating in a randomized do…

OncologyAdultMalemedicine.medical_specialtyMirtazapineSingle-nucleotide polymorphismMirtazapineMianserinPharmacologyDouble-Blind MethodInternal medicinemedicineHumansMonoamine OxidaseBiological PsychiatryAllelesPharmacologyPsychiatric Status Rating ScalesDepressive Disorder MajorbiologyReverse Transcriptase Polymerase Chain ReactionDNAMiddle AgedMianserinParoxetineAntidepressive AgentsIntronsParoxetineData Interpretation Statisticalbiology.proteinAntidepressantFemaleMonoamine oxidase BMonoamine oxidase APsychologyPharmacogeneticsSelective Serotonin Reuptake Inhibitorsmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depressio…

2011

Abstract In Major Depressive Disorder, a growing data base suggests that the onset of antidepressants’ action can be detected by improvement of depressive symptoms in the first 10–14 days of treatment. Previous studies showed that the mean concentration of the brain-derived neurotrophic factor (BDNF) in blood increases during antidepressant treatment and positively correlates with amelioration of MDD symptoms. We previously showed an association between very early changes of the serum BDNF concentration and treatment outcome ( Tadic et al., 2011 . Prog Neuropsychopharmacol Biol Psychiatry 35, 415–420). However, no study has yet investigated whether BDNF concentration in plasma increases in …

OncologyAdultMalemedicine.medical_specialtyTime FactorsEnzyme-Linked Immunosorbent AssayCellular and Molecular NeuroscienceYoung AdultNeurotrophic factorsInternal medicineHamdmedicineHumansPsychiatryDepression (differential diagnoses)PharmacologyBrain-derived neurotrophic factorPsychiatric Status Rating ScalesDepressive Disorder MajorInpatientsBrain-Derived Neurotrophic FactorMiddle Agedmedicine.diseaseAntidepressive AgentsROC CurveLinear ModelsAntidepressantBiomarker (medicine)Major depressive disorderAnxietyFemalemedicine.symptomPsychologyNeuropharmacology
researchProduct

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubi…

2010

International audience; Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated whether adjuvant epirubicin (E) followed by CMF is superior to the inverse sequence in RPBC. Patients with node-negative or 1-3 node-positive RPBC (Thymidine Labeling Index > 3% or histological grade 3 or S-phase > 10% or Ki67 > 20%) were randomized to receive E (100 mg/m i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m i.v. d1 and 8, q2…

OncologyCancer ResearchSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRandomized phase III study0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsCMFMedicineProspective Studies0303 health sciencesCMF; Epirubicin; Randomized phase III study; Rapidly proliferating breast cancer; Sequential adjuvant chemotherapy strategySequential adjuvant chemotherapy strategy – Epirubicin – CMF – Randomized phase III study – Rapidly proliferating breast cancerSequential adjuvant chemotherapy strategyHazard ratioMiddle Aged3. Good healthTreatment OutcomeReceptors EstrogenOncologyFluorouracilLymphatic Metastasis030220 oncology & carcinogenesisFemaleFluorouracilBreast diseaseRapidly proliferating breast cancermedicine.drugEpirubicinAdultmedicine.medical_specialtyCyclophosphamidebreast cancer epirubicinBreast NeoplasmsNeutropeniaModels Biological03 medical and health sciencesBreast cancerInternal medicineHumansCyclophosphamideAgedProportional Hazards ModelsEpirubicin030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseSurgeryMethotrexatebusinessBreast Cancer Research and Treatment
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index &gt;3% or G3 or Ki67 &gt;20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Addressing the importance of melanoma tumor‑infiltrating lymphocytes in disease progression and clinicopathological characteristics

2021

Tumor-infiltrating lymphocytes (TILs) in primary cutaneous melanoma are considered to represent the host's antitumor immunological response; however, whether there are associations between TIL grade and histopathological characteristics and disease survival remains controversial. BRAF mutational status has been established as a routine screening method in advanced malignant melanoma, and worse prognosis rates have been demonstrated in patients harboring BRAF mutations. However, the general impact of BRAF mutational status on survival and histopathological characteristics is still debated. The aim of the present study was to compare the value of the assessment of TIL grade in stages I-II nod…

OncologyCancer Researchmedicine.medical_specialtyTumor-infiltrating lymphocytesbusiness.industryMelanomaHazard ratioCancerBRAF V600ArticlesDiseasemedicine.diseaseSuperficial spreading melanomaOncologytumor infiltrating lymphocytesInternal medicineCutaneous melanomamelanomahistopathologymedicineStage (cooking)businessneoplasmsMolecular and Clinical Oncology
researchProduct

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer

2021

Background Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment in cancer. In this study, we evaluate the potential of miR-30b-5p as a biomarker for early diagnosis of breast cancer (BC) in tissue and plasma. Methods Expression of miR-30b-5p was determined in a series of 112 BC and 40 normal breast tissues. Circulating miR-30b-5p levels in plasma samples were determined in a discovery cohort of 38 BC patients and 40 healthy donors and in a validation cohort of 83 BC patients and 83 healthy volunteers. miR-30b-5p expression was measured by quantitative real-time PCR and receiver operating…

OncologyCancer Researchmedicine.medical_specialtydiagnosisBreast NeoplasmsBreast cancerbreast cancerPositive axillary lymph nodeInternal medicinemicroRNAmedicineBiomarkers TumorHumansStage (cooking)plasmaEarly Detection of CancerOriginal ResearchReceiver operating characteristicmicroRNAbusiness.industryCancermedicine.diseasePrognosisMicroRNAsOncologyCohortBiomarker (medicine)FemalebusinessESMO Open
researchProduct

Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.

2017

The purpose of this study was to investigate the role of features derived from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to incorporated clinical information to predict the molecular subtypes of breast cancer. In particular, 60 breast cancers with the following four molecular subtypes were analyzed: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-over-expressing and basal-like. The breast region was segmented and the suspicious tumor was depicted on sequentially scanned MR images from each case. In total, 90 features were obtained, including 88 imaging features related to morphology and texture as well as dynamic features from tumor and …

OncologyCancer Treatmentlcsh:MedicineInvasive Ductal CarcinomaLogistic regression030218 nuclear medicine & medical imagingDiagnostic Radiology0302 clinical medicineMathematical and Statistical TechniquesBreast TumorsImage Processing Computer-AssistedMedicine and Health Scienceslcsh:ScienceMultidisciplinarymedicine.diagnostic_testHuman epidermal growth factorRadiology and ImagingMiddle AgedMagnetic Resonance ImagingOncology030220 oncology & carcinogenesisArea Under CurvePhysical SciencesFemaleAlgorithmsStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyImaging TechniquesImage processingBreast NeoplasmsResearch and Analysis MethodsCarcinomasSkewness03 medical and health sciencesBreast cancerText miningDiagnostic MedicineInternal medicineImage Interpretation Computer-AssistedBreast CancermedicineBiomarkers TumorHumansStatistical MethodsDifferentiated TumorsAgedNeoplasm StagingReceiver operating characteristicbusiness.industrylcsh:RCancers and NeoplasmsMagnetic resonance imagingLuminal amedicine.diseaseImage EnhancementProbability TheoryProbability Distributionlcsh:QNeoplasm GradingbusinessMathematicsForecastingPloS one
researchProduct

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX ch…

2013

The GOLFIG-2 phase III trial was designed to compare the immunobiological activity and antitumor efficacy of GOLFIG chemoimmunotherapy regimen with standard FOLFOX-4 chemotherapy in frontline treatment of metastatic colorectal cancer (mCRC) patients. This trial was conceived on the basis of previous evidence of antitumor and immunomodulating activity of the GOLFIG regimen in mCRC. GOLFIG-2 is a multicentric open/ label phase III trial (EUDRACT: 2005-003458-81). Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m 2, day 1); oxaliplatin (85 mg/m2, day 2); levofolinate (100 mg/m2, days 1-2), 5-fluorouracil (5-FU) (400…

OncologyMaleCancer ResearchGranulocyte-macrophage-colonystimulating- factorOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinColorectal NeoplasmGastroenterologyDeoxycytidineFOLFOXAldesleukinPhase iii trialAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineChemoimmunotherapyNeoplasm MetastasisAged 80 and overAldesleukinMiddle AgedNeoplasm MetastasiOxaliplatinColorectal carcinomaTreatment OutcomeFluorouracilFemaleFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultmedicine.medical_specialtyImmunologyLymphocytes Tumor-InfiltratingChemoimmunotherapyInternal medicineHumansAgedPharmacologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundGranulocyte-Macrophage Colony-Stimulating FactorGemcitabineGemcitabineOxaliplatinRegimenInterleukin-2Neoplasm GradingbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Expression of cell cycle markers and human papillomavirus infection in oral squamous cell carcinoma: use of fuzzy neural networks.

2005

Our aim was to evaluate in oral squamous cell carcinoma (OSCC) the relationship between some cell cycle markers and HPV infection, conditionally to age, gender and certain habits of patients, and to assess the ability of fuzzy neural networks (FNNs) in building up an adequate predictive model based on logic inference rules. Eighteen cases of OSCC were examined by immunohistochemistry for MIB-1, PCNA and survivin expression; presence of HPV DNA was investigated in exfoliated oral mucosa cells by nested PCR (nPCR, MY09-MY11/GP5-GP6), and HPV genotype was determined by direct DNA sequencing. Data were analyzed by traditional statistics (TS) and FNNs. HPV DNA was found in 9/18 OSCCs (50.0 %) wi…

OncologyMaleCancer ResearchSurvivinmedicine.disease_causeInhibitor of Apoptosis ProteinsRisk FactorsOral mucosaPapillomaviridaeAged 80 and overCell CycleSmokingHPV infectionAge FactorsAnatomical pathologyCell cycleMiddle AgedImmunohistochemistryNeoplasm Proteinsoral squamous cell carcinomamedicine.anatomical_structureCell Transformation NeoplasticOncologyCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmscarcinogenesisMicrotubule-Associated ProteinsAdultmedicine.medical_specialtyBiologySex FactorsFuzzy LogicInternal medicineSurvivinmedicineHumanshuman papillomaviruAgedfuzzy neural networkGene Expression ProfilingPapillomavirus Infectionsmedicine.diseaseProliferating cell nuclear antigenstomatognathic diseasesImmunologyDNA Viralbiology.proteinNeural Networks ComputerCarcinogenesisInternational journal of cancer
researchProduct